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Background: Concurrent chemoradiation is a standard option for locally advanced pancreatic cancer (LAPC).
Concurrent conventional radiation with full-dose gemcitabine has significant toxicity. Stereotactic body radiation
therapy (SBRT) may provide the opportunity to administer radiation in a shorter time frame with similar efficacy and
reduced toxicity. This Pilot study assessed the safety of concurrent full-dose gemcitabine with SBRT for LAPC.
Methods: Patients received gemcitabine, 1000 mg/m2 for 6 cycles. During week 4 of cycle 1, patients received
SBRT (25 Gy delivered in five consecutive daily fractions of 5 Gy prescribed to the 75-83% isodose line). Acute and
late toxicities were assessed using NIH CTCAE v3. Tumor response was assessed by RECIST. Patients underwent an
esophagogastroduodenoscopy at baseline, 2, and 6 months to assess the duodenal mucosa. Quality of life (QoL)
data was collected before and after treatment using the QLQ-C30 and QLQ-PAN26 questionnaires.
Results: Between September 2009 and February 2011, 11 patients enrolled with one withdrawal during radiation
therapy. Patients had grade 1 to 2 gastrointestinal toxicity from the start of SBRT to 2 weeks after treatment. There
were no grade 3 or greater radiation-related toxicities or delays for cycle 2 of gemcitabine. On endoscopy, there
were no grade 2 or higher mucosal toxicities. Two patients had a partial response. The median progression free and
overall survival were 6.8 and 12.2 months, respectively. Global QoL did not change between baseline and
immediately after radiation treatment.
Conclusions: SBRT with concurrent full dose gemcitabine is safe when administered to patients with LAPC. There is
no delay in administration of radiation or chemotherapy, and radiation is completed with minimal toxicity.
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Quality of life (QoL) is of paramount importance
when cure is not achievable, as is currently the case
with locally advanced pancreatic cancer (LAPC). In
the United States, concurrent chemoradiation therapy
is commonly considered the standard of care for LAPC
patients, but outcomes are still poor. Randomized clinical
trials of chemoradiation vs. chemotherapy alone have
shown mixed results, with some trials showing a survival
benefit with chemoradiation [1-4] and others demon-
strating that is has a negative impact on overall survival
[5,6]. Furthermore, in trials in which there was a
survival advantage, toxicity was often higher in the
chemoradiation arm [1,3,4]. Therefore, clinicians and
patients must weigh the small potential gain in over-
all survival versus the potential adverse effects with
chemoradiation.
Traditionally, chemoradiation trials include the use of
conventional external beam radiation. This technique
uses large radiation fields that deliver a high percentage
of the prescription dose to surrounding critical structures
possibly leading to significant toxicity and decreased
quality of life. When irradiating abdominal tumors with
conventional external beam radiation, strict adherence
to normal structure dose constraints may limit the
delivery of the intended radiation dose to the tumor
and potentially result in premature local failure and
death. Conversely, delivering high doses of radiation
to adjacent critical structures without strict dose constraints
increases the risk of late radiation induced complications.
Intensity-modulated radiation therapy (IMRT) has made
advances over 3D conformal treatment in protecting critical
structures and reducing toxicity [7,8]; however grade 3 and
4 toxicities are still reported and treatment breaks are
required that may reduce the treatment’s effectiveness.
Tumor motion due to respiration [9] and unpredictable
gastrointestinal distention [10], require large IMRT plan-
ning target volume expansions that limit the maximum
prescription dose. Furthermore, daily IMRT treatments
for approximately six weeks can be taxing to these ill
patients and their families and society [11]. SBRT may
prevent local progression of disease while sparing nearby
critical structures, thus providing an improved durable
QoL. Furthermore, SBRT is an appealing option for LAPC
since it allows reduced treatment times. Previous studies
have investigated SBRT (25 Gy in one fraction) as a boost
to IMRT with concurrent 5-FU, and SBRT monotherapy
(25 Gy in one fraction) with gemcitabine [12,13]. In
both of these trials, local control was excellent; however,
late duodenal toxicity was significant, and was related
to the amount of duodenum irradiated [14]. Median
overall survival was comparable to modern expected
outcomes [4,15,16]. In an effort to decrease late duo-
denal toxicity, we and others [17-20], have examined theuse of fractionated SBRT with full dose gemcitabine.
Here, we report the results of our feasibility trial.
Methods
Patients
Patients with biopsy-proven, non-metastatic, unresectable
pancreatic adenocarcinoma who had an adequate per-
formance status and normal hepatic and renal function
were eligible for enrollment on this study. Unresectable
disease was defined as any greater than 180° encasement
of the celiac, superior mesenteric, hepatic, or gastroduodenal
arteries, or greater than 2 cm involvement of the portal or
splenic veins, or any venous tumor thrombus. Patients
with duodenal mucosal involvement (at time of initial
endoscopy) were excluded. The Georgetown University
institutional review board approved this study and all
patients provided informed written consent.
Treatment summary
Figure 1 provides a schematic overview of patient treat-
ment. Eligible patients first underwent an esophagogas-
troduodenoscopy with endoscopic ultrasound (EGD/
EUS) with placement of gold fiducial markers required
for SBRT. Gemcitabine, 1000mg/m2, was delivered on
day 1 and day 8 (cycle 1, weeks 1 and 2 of gemcitabine).
Prior to day 15 (cycle 1, week 3 of gemcitabine), patients
underwent a CT scan for SBRT treatment planning.
Patients then received day 15 gemcitabine (cycle 1, week
3), and during the subsequent “off” week from chemo-
therapy (cycle 1, week 4) the patients received SBRT.
Cycle 2 of gemcitabine was administered without a
planned treatment delay, followed by restaging scans
and EGD/EUS to assess tumor response and acute
mucosal toxicity. Patients, who were tolerating therapy
and without progression as determined by RECIST cri-
teria [21], continued gemcitabine with restaging scans
every two cycles, to a maximum of 6 cycles. One add-
itional EGD/EUS was performed after 6 cycles to assess
late toxicities of SBRT.
SBRT
SBRT treatment was delivered with the CyberKnife
(Accuray Incorporated, Sunnyvale, CA) which uses real
time tumor tracking and requires 3 visible, non-
collinear fiducials on the orthogonal x-ray images [22].
Three to five gold fiducials were placed endoscopically
in the pancreatic mass as previously described [23].
Seven days after fiducial placement, fine-cut (1.25 mm)
treatment planning CT’s with oral and IV contrast were
obtained during a full inhalation breath hold.
The gross target volume (GTV) included the pancre-
atic mass (Figure 2). The SBRT planning target volume
(PTV) equaled the GTV plus the adjacent vasculature
(AV) without expansion. The AV is the area of vasculature
Figure 1 Schema: treatment algorithm and tumor assessment.
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and posterior nodal regions (posterior pancreaticoduo-
denal, superior mesenteric, and para-aortic nodes) at
the level of the pancreatic mass. Surgical series have
demonstrated a high probability of metastases to these
regions with 32.31%, 15.85 %, and 10.92%, respectively
[25]. Furthermore, the mesopancreas is the primary site
for an R1 resection [26]. Therefore, this elective volume
was included in increase the probability of an R0 resec-
tion if any patients were deemed resectable after
chemoradiation. Given the sub-millimeter precision of
CyberKnife treatment [22], no uniform expansion was
added to correct for set-up inaccuracy. Instead the
initial contours of the GTV were generous becauseFigure 2 CyberKnife treatment planning for patient #2: A. Axial comp
volume (yellow), adjacent vascular volume (red), duodenum (green),
lines shown as follows: Blue 81% (prescription), white 70% and purple 50%computed tomography scans significantly under-represent
pancreatic tumor size [27]. SBRT with respiratory tracking
was administered as previously described for lung tumors
[28]. The prescription dose was 25 Gy delivered to the
PTV in 5 fractions of 5 Gy over 5 days. The volume of
the PTV receiving 25 Gy, termed the V25 Gy, was to be
at least 95%. Variations of the V25 Gy that were less
than 95%, but greater than or equal to 90%, were
considered minor variations; whereas variations to the
V25 Gy that were less than 90% were considered major
variations. The prescription isodose line was limited
to ≥ 75% which restricted the maximum tumor dose
to 133% of the prescription dose. The duodenal and
adjacent bowel volumes receiving 25 Gy were limiteduted tomography images demonstrating the gross tumor
stomach (orange), spinal cord (pink) and kidneys (blue). B. Isodose
.
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was ≥ 1 cc and < 2 cc; variations were considered major
if the V25 Gy was > 2 cc (Table 1).
Toxicity assessment
Toxicity was scored according to the National Cancer In-
stitute Common Terminology Criteria for Adverse Events,
Version 3.0. Due to the lack of a systematic endoscopic
grading system for radiation induced mucosal injury, a
previously developed descriptive based scoring system
[29] was used to evaluate for extent of telangiectasia,
congested mucosa, ulceration, stricture and necrosis.Quality of life assessment
All patients were asked to complete two quality of life
questionnaires: the EORTC QLQ-C30 version 3 and
EORTC QLQ-PAN26, on the first day of each chemo-
therapy cycle. The QLQ-C30 measures generic health
status. QLQ-PAN26 is a pancreatic cancer treatment
specific instrument that assesses patient function and
bother [30].
Statistical analysis
Baseline characteristics and adverse events were tabulated.
Adverse events were described for each symptom
according to Wachter, et al. [29] and the NCI CTCAE
version 3.0. Each symptom was counted once per pa-
tient at the highest grade it occurred. Progression-Free
Survival (PFS) was calculated as the date gemcitabine
was started to the date of progression or death, which-
ever came first. Overall survival (OS) was calculated
from the start date of gemcitabine to date of death.
Since patients were followed until death, no censoring
occurred for PFS or OS. OS and PFS were calculated
using the Kaplan-Meier method [31]. Median OS and
PFS times were reported with 95% confidence intervals













Isodose Line 78% 10 0 0
PTV (V25Gy) 95.5% 10 0 0






Mean percent target coverage, prescription isodose line and critical structure
dose/volume results and minor and major variations from protocol.of the primary on serial radiologic imaging. Wilcoxon rank
sum test was used to assess QoL score changes.
Results and discussion
Patient and tumor characteristics
Fourteen patients were screened and three patients
were not enrolled for the following reasons: 1) Identifi-
cation of metastatic disease; 2) Liver transaminitis;
and 3) Inability to endoscopically place fiducials due
to a previously placed duodenal stent. One patient,
who was 81 years of age, withdrew due to significant
decrease in performance status after just two radiation
treatments so an 11th patient was enrolled for 10
evaluable patients. These patients were treated over a
period extending from September 2009 to February 2011
(Table 2) and were followed until death. The mean age
at enrollment was 62.5 years (range 50 – 79 years). Nine
patients had an ECOG performance status (PS) 1 and
one patient was an ECOG PS 0. All the tumors involved
the pancreatic head or body and six patients also had
clinically involved lymph nodes.
SBRT
All patients completed SBRT as prescribed. The mean
PTV was large with a mean volume of 360 cc (range,
154 cc – 548 cc) and the mean GTV was 175 cc (range,
103 – 336 cc) (Table 1). Radiation was delivered to a
mean prescription isodose line of 78% (range, 75% -
83%) in 5 treatments (Table 1). The mean percent target
coverage was 95.42%. Treatment plans were conformal
with a mean new conformity index (the target volume
multiplied by the prescription isodose volume divided by
the target volume covered by prescription isodose vol-
ume squared [32]) of 1.39. Plans were inhomogeneous
by design (mean homogeneity index of 1.28) to minimize
dose to adjacent critical structures. There were no major
protocol variations; one minor protocol variation oc-
curred when 1.0 cc of duodenum received 25 Gy
(Table 1).
From the start of SBRT and for 1–2 weeks thereafter,
patients generally exhibited grade 1–2 nausea and ab-
dominal cramping, but there were no grade 3 radiation-
related acute toxicities, and cycle 2 of gemcitabine was
not delayed. Serial endoscopy showed 60% of patients
had asymptomatic, small mucosal ulcerations (Grade 1)
at 2 months. Of the five patients who completed endos-
copy at six months one patient had residual grade one
mucosal congestion. There were no grade 2 or higher
mucosal toxicities.
Chemotherapy
Overall, 8 of 10 patients completed 6 cycles of gemcitabine,
although all patients required dose reductions or schedule
modifications, mostly due to myelosuppression from the
Table 2 Patient characteristics
Patient Age Sex ECOG Location Lymph nodes
1 62 M 1 Head N1
2 79 F 1 Head & Body N1
3 Withdrew before completing radiation
4 Screening failure due to metastatic disease
5 74 M 1 Body N1
6 50 M 1 Body N0
7 63 F 0 Head N1
8 56 F 1 Head N1
9 63 M 1 Head N0
10 76 M 1 Head N1
11 Screening failure due to elevated liver function.
12 Screening failure due to inability to place fiducials.
13 57 F 1 Head N0
14 62 F 1 Head N0
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all six cycles, one patient became critically ill during cycle
three, was admitted for sepsis and taken off study. The
other patient progressed with distant metastases after
chemotherapy cycle five and was changed to an alternative
chemotherapy regimen.Patient outcomes
All patients were followed until death. Two patients
had a partial response by RECIST. None of the patients
were rendered resectable. All but one patient experienced
disease progression by RECIST with a median time to
progression of 6.8 months (95% CI: 2.8, 10.3 months).
Four patients experienced local progression as the first







1 SD 189 Local + distant
2 PR 317 Local
5 SD 470 Distant
6 SD 228 Distant
7 SD 176 Distant
8 PR 450 Local
9 SD 251 Distant
10 PD 66 Local
13 SD 168 Distant
14 SD 121 Distantlocal progression before death (Table 3). The median
survival was 12.2 months (95% CI: 4.4, 15.2 months)
(Figure 3). Of the patients who completed all cycles,
one patient received maintenance chemotherapy with
capecitabine and three patients received salvage chemo-
therapy and/or conventional radiation therapy (39 cGy
in 1.8 Gy fractions) at the time of progression. Patients
who did not receive salvage therapy either opted not to
or were too sick to do so (Table 3).Quality of life
Of the eight patients who received all six chemotherapy
cycles, only four patients completed both the EORTC
QTC 30 and PAN 26 questionnaires for all chemotherapy
cycles, which limited the analysis to the first three
chemotherapy cycles. QoL scores immediately after SBRT
showed a statistically significant increase from baseline for
fatigue, nausea/vomiting (N/V) and anorexia (p < 0.05).
The declines in fatigue and anorexia QoL were no longer
statistically different from baseline by chemotherapy
cycle 3. Symptoms did not improve significantly after
radiation therapy; however, there was a trend towards
improved back pain, night pain and abdominal discom-
fort. Global QoL did not change significantly from base-
line due to radiation treatment (Figure 4).
In pancreatic cancer, improved methods of controlling
the primary cancer are needed as local progression ad-
versely affects the length and quality of life. Dose escal-
ation with standard external beam radiation therapy has
been attempted [33]. However, the inability to limit nor-
mal tissue doses led to severe life-threatening toxicity.
On the other hand, standard radiation treatment for 5–
6 weeks prolongs treatment time and delays adminis-
tration of systemic therapy. Recent data suggest that large
radiation fraction sizes are radio-biologically favorableSalvage therapy Time to death
(days)
None 254
Capecitabine (maintenance); Radiation 440
None 490
FOLFOX 397





Progressed on gemcitabine, switched to lapatinib +
capecitabine
305
Figure 3 Kaplan-Meier plot of (A) progression-free survival
(PFS) and (B) overall survival (OS).
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pancreatic cancer [34,35]. This is supported by trials that
achieved improved pancreatic cancer local control rates
by utilizing large fraction sizes with intraoperative radi-
ation therapy or brachytherapy [36-42]. Analysis of these
data suggested that radiobiologic dose escalation to the
tumor volume could improve local control in pancreatic
cancer.
Gemcitabine is a potent pancreatic cancer radiosensitizer
[43]. As previously shown, by the Eastern Cooperative
Oncology Group, in patients with LAPC, concurrent
gemcitabine at a reduced dose (600 mg/m2) and radi-
ation (50.4 Gy in 28 fractions) provided survival benefit
over gemcitabine (1000 mg/m2) alone (4). Furthermore,
full dose gemcitabine (1000 mg/m2/week) with concur-
rent radiation therapy has been shown to be feasible
and safe with the omission of elective nodal irradiation
and radiation dose reductions [15]. The combination
of full dose gemcitabine with radiation therapy should
enhance local and systemic tumor control.In our study, patients received full dose gemcitabine
(1000 mg/m2) and concurrent SBRT with an included
elective nodal volume The radiation dose given was 25
Gy in five consecutive fractions, which is an equivalent
dose in 2 Gy fractions of approximately 40 Gy. We felt
that this would be a safe but effective dose drawing
from the University of Michigan’s IMRT dose escalation
trial. In their trial the MTD was determined to be 36
Gray given in 2.4 Gray fractions, which is equivalent to
41.4 Gray in 1.8 Gray fractions [44]. Furthermore, the
inhomogenity is much greater with SBRT than IMRT
and consequently the central tumor dose is significantly
higher than the prescription dose to the periphery.
Hypofractionated stereotactic body radiation therapy
was completed in one week in all patients. Critical
organs including the bowel, liver, spinal cord, and kidneys
were spared. There were no grade 3 or 4 acute toxicities
secondary to radiation and the initiation of the second
cycle of chemotherapy was not delayed. Our protocol
had strict duodenal dose restrictions and additionally
monitoring for late toxicity by endoscopy was performed.
With our dose limitations no late toxicity was observed.
Chemotherapy toxicity from full dose gemcitabine was
as expected with the majority secondary to adverse
hematologic effects. However, our local control was
lower than that achieved with a single fraction of 25 Gy.
This is despite the fact that our patients received con-
current full dose (1000 mg/m2) gemcitabine rather than
sequential chemotherapy. This may be due to the rela-
tively low biological effective dose used in this trial.
Despite the lower local control, our median progression
free survival and overall survival of 6.8 and 12.2 months
are comparable to contemporary chemoradiation trials.
Quality of life scores were difficult to interpret due to
the small number of patients that completed all the
questionnaires. This could have biased the results since
patients who progressed were taken off study and did
not complete the questionnaires and patients too ill to
complete the questionnaires would most likely report
lower QOL scores.Conclusions
Our results from this pilot study demonstrate the feasi-
bility and tolerability of delivering SBRT with concurrent
full dose gemcitabine. Unfortunately, local and distant
progression remains the predominant patterns of failure
for these patients. Nonetheless, SBRT remains a useful
tool to optimize available treatment for patients with
tumors in close proximity to critical structures while
maintaining QOL. Additional studies combining SBRT
with regimens that have been proven to improve the
control of systemic disease, such as FOLFIRINOX, are
also being evaluated [45].
Figure 4 Quality of life. Number of patients who had improvement, no change, or worsening between baseline and immediately after SBRT
and from baseline to one month after SBRT. Numbes may not add to 10 due to incomplete questionnaires.
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the efficacy of this treatment. While outcomes were com-
parable to contemporary trials, this study only included
ten patients. Furthermore, the SBRT dose used in this trial
is currently lower than what our institution is safely using
at this time. With the low toxicity profile experienced by
patients on this trial we will increase the SBRT dose and
our future trial will most likely treat patients in five con-
secutive fractions of 6 Gy per fraction. This will hopefully
provide improved local control. While there is still an
issue with controlling distant disease, local tumor progres-
sion leads to significant morbidity.
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